^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RBX7455 intratumoral

    i
    Other names: RBX7455 intratumoral
    Associations

    News

    Trials
    Company:
    Ferring
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    4years
    RBX7455: A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug (clinicaltrials.gov)
    P1, N=30, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • IND
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 amplification
    |
    RBX7455 intratumoral
    over4years
    RBX7455: A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Mayo Clinic | Initiation date: Mar 2020 --> Jul 2020
    Clinical • IND • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 amplification
    |
    RBX7455 intratumoral
    almost5years
    RBX7455: A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Mayo Clinic | Initiation date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2021 --> Mar 2022
    Clinical • IND • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 amplification
    |
    RBX7455 intratumoral